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Gy/fraction, twice- daily to a total dose of 10-20 Gy (one 
week apart) according to the dose of the external beam 
radiotherapy. The total dose ranged from 76-84 Gy when 
transformed to EQD2 models. Patients were followed up by 
contrast-enhanced CT or MRI 4 weeks and then every 3 
months after the end of treatment. The primary end point 
was local tumor control. Secondary end points of the adverse 
events, distant metastases and progression-free survival were 
also included. 
 
Results: The first follow-up examination after 4 weeks 
revealed 10/11 coverage of all nodal metastases treated. 
There was no peri-interventional mortality or major 
complications. The mean follow-up period was 12.2 months 
(range 7–15 months). After a median follow up of three 
months, the median local tumor control was 90%. 2 out of 10 
patients (20%) showed local tumor progression 6 and 8 
months after brachytherapy. 2 patients (20%) who died of 
distant metastasis. The grade III-IV complications occurred in 
1 patient (10%). The mean progression-free interval was 13 
months (range 6–16 months).  
 
Conclusion: We consider that the interstitial brachytherapy 
technical will provide a relative high and accurate dose 
irradiation to bulky lymph node metastasis for improving the 
local tumor control in patients with different solid cancers. 
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Purpose or Objective: Commissioning of HDR brachytherapy 
treatment equipment is essential to avoid errors and assure 
quality. However, it is estimated that worldwide, less than 
one-quarter of centres undertake robust local commissioning 
tests at installation [1], important checks may be omitted 
[2], or systematic errors may remain [3]. The purpose of this 
work is to: (i) reinforce the need for local HDR commissioning 
and propose a list of recommended tests; (ii) publish results 
of the commissioning for a new-to-market HDR brachytherapy 
system from two centres. 
 
Material and Methods: A literature review was conducted on 
existing guidance for HDR system commissioning, HDR 
treatment errors and known factors affecting sub-optimal 
quality. The case for robust local commissioning of HDR 
equipment was assessed in terms of mitigating potential 
errors and improving quality of treatment delivery. A 
schedule of required commissioning tests was established and 
implemented at two centres, in England and Germany, for 
the commissioning of a new HDR brachytherapy treatment 
system, SagiNova (Eckert & Ziegler Bebig GmbH) with Co-60 
sources. 
 
Results: Evidence was found that errors do occur [4], 
particularly in the absence of robust commissioning and QC. 
There is little contemporary guidance for commissioning of 
HDR brachytherapy treatment equipment, which is required 
to build on the QC guidance in ESTRO Booklet No. 8 from 
2004. The table provides our proposal for efficient, robust, 
and easily implemented commissioning tests. For the 
SagiNova system, results from the two centres showed 
satisfactory performance in all tests. The mean error for 
source dwell positions in straight catheters was 0.5 mm (±0.5 
mm k=2) and in clinical treatment applicators was 0.6 mm 
(±1.0 mm k=2) compared to TPS planned positions. The ‘end 
to end’ system check with IPEM ‘BRAD’ system [5] had 
prescription point <0.4% (±2.5% k=2) and 97% gamma pass 
rate (3%, 2mm) compared to TPS calculations. By comparing 
results between centres a quality improvement was 
identified and implemented comprising an update of the 
dwell-position database at one centre. 
 
 
Conclusion: It is not sufficient to rely on type-testing by 
manufacturers and instead local commissioning must be 
implemented to assure quality and mitigate the risk of 
treatment errors in HDR brachytherapy. Suitable tests are not 
always performed and a schedule of minimum commissioning 
tests has been proposed. The first two installations of the 
new SagiNova HDR system demonstrated clinically acceptable 
results. An improvement of the source dwell database was 
identified, confirming the value of interdepartmental checks 
and robust commissioning. 
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Purpose or Objective: To simplify technical design of 
brachytherapy water phantom for performing absolute 
dosimetry using standard instruments and equipment 
available in radiotherapy department. To perform absolute 
measurements for source-to-ionization chamber distance ~ 4 
cm. 
 
Material and Methods: CNMC WP-380 water tank used for 
locating ionization chamber and the holder of the radioactive 
source. To minimize dimensional correction factors for 
ionization chamber it was taken 0,125 cm3 PTW 31010 
ionization chamber. For reducing uncertainty of the source 
position inside mould probe we used “curved catheter” 
method in the design of the catheter holder to make an 
effect of “pressing down” the end part of cable to lower wall 
of the probe. Holder designed in this way that amount of 
other than water surrounding source material was maximally 
reduced. Source-to-ionization chamber distance was set by 
